MAP Share Price Performance
AU$0
-0.19 (-100.00%)
Price AU$0
Fair ValueAU$0.29
Share Pricen/a
Microba Life Sciences Limited (ASX:MAP) Not Flying Under The Radar
Nov 09
Microba Life Sciences Limited Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
MAP Community Narratives
AN
Fair Value AU$0.29 74.8% undervalued intrinsic discount
Gut Microbiome Diagnostics Will Drive Powerful Long-Term Upside Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Gut Microbiome Diagnostics Will Drive Powerful Long-Term Upside Potential
Catalysts About Microba Life Sciences Microba Life Sciences provides advanced clinical microbiome diagnostics and therapeutic assets to improve outcomes for patients with chronic gastrointestinal and other diseases. What are the underlying business or industry changes driving this perspective?Read more
1
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AU$0.29
74.8% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
34.25% p.a.
Profit Margin
4.78%
Future PE
122.58x
Price in 2028
AU$0.28
Trending Discussion
Recently Updated Narratives
AN
Gut Microbiome Diagnostics Will Drive Powerful Long-Term Upside Potential
Fair Value: AU$0.29 74.8% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Microba Life Sciences Limited Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.025
- 47.49%
- -95.34%
- 3.7%
About MAP
- Founded
- 2017
- Employees
- n/a
- CEO
- WebsiteView website
Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; MetaXplore that provides a range of diagnostics solution under the Co-Biome brand; research testing services; and data-driven therapeutics platform that develops therapies for ulcerative colitis, and inflammatory bowel and autoimmune diseases, as well as microbiome databank. Microba Life Sciences Limited was incorporated in 2017 and is based in Brisbane, Australia.
